Anna Spreafico depicts her personal highlights regarding immunotherapy plus chemotherapy or intensity-modulated radiotherapy for people with locally advanced nasopharyngeal cancer (NPC) at this year’s ASCO meeting, discusses if longitudinal plasma EBV DNA monitoring should be incorporated into the guidance of personalized disease management and future clinical trials, highlights the most promising agents explored in the 1L treatment of recurrent/metastatic NPC and overviews how the prognosis of those patients will evolve in the years to come.

Here is the full ASCO 2022 Solid Tumors report.